184 related articles for article (PubMed ID: 16033052)
1. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
Schneider J; Bitterlich N; Schulze G
Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
[TBL] [Abstract][Full Text] [Related]
2. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
3. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
Schneider J; Schulze G
Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
[TBL] [Abstract][Full Text] [Related]
5. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
[TBL] [Abstract][Full Text] [Related]
6. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
7. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
Schulze G
Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
[TBL] [Abstract][Full Text] [Related]
8. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer.
Schneider J; Bitterlich N; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Int J Clin Oncol; 2002 Jun; 7(3):145-51. PubMed ID: 12109515
[TBL] [Abstract][Full Text] [Related]
9. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease.
Halm U; Rohde N; Klapdor R; Reith HB; Thiede A; Etzrodt G; Mössner J; Keller T
Anticancer Res; 2000; 20(6D):4957-60. PubMed ID: 11326646
[TBL] [Abstract][Full Text] [Related]
10. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
11. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
Hardt PD; Ewald N
Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
[TBL] [Abstract][Full Text] [Related]
12. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
13. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
[TBL] [Abstract][Full Text] [Related]
14. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
15. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
[TBL] [Abstract][Full Text] [Related]
16. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
Kumar Y; Gurusamy K; Pamecha V; Davidson BR
Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK
Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
[TBL] [Abstract][Full Text] [Related]
18. Detection of lung cancer in silicosis patients using a tumor-marker panel.
Schneider J
Cancer Biomark; 2010; 6(3-4):137-48. PubMed ID: 20660960
[TBL] [Abstract][Full Text] [Related]
19. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
Schneider J; Velcovsky HG; Morr H; Katz N; Neu K; Eigenbrodt E
Anticancer Res; 2000; 20(6D):5053-8. PubMed ID: 11326667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]